Altogether, mRNA-LNP treatments during CDE-induced chronic injury demonstrate the clinical benefit of injections of HGF/EGF mRNA-LNP to sharply eliminate the NAFLD characteristics such as lipid accumulation and liver damage. The gene discussed is HGF; the disease is metabolic dysfunction-associated steatotic liver disease.